Tables
- TABLE 1
Demographic and clinical details of 21 recruited patients with sarcoidosis
Age years 57 (48–71) Male/female 9/12 Years since diagnosis 3 (1–13) Scadding chest radiography stage 1/2/3 2/6/12 FEV1 % predicted 87.5 (52–131) FVC % predicted 91.5 (63–128) FEV1/FVC ratio 0.75 (0.55–0.93) QTc interval ms 427 (370–463) Oral corticosteroid therapy 4 Other immunomodulatory therapy 0 Inhaled corticosteroids 3 Number of coughs in 24 h 228 (43–1950) Number of coughs·h−1 10 (2–81) Cough severity VAS mm 31 (9–94) Urge to cough VAS mm 26 (8–94) Leicester cough questionnaire score 15.96 (5.07–19.74) King's sarcoidosis questionnaire GH score 50.7 (23.8–100) Data are presented as median (range) or n. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; VAS: visual analogue scale.
- TABLE 2
Secondary end-points
Baseline 1 month 3 months Change from baseline to 3 months p-value (Friedman's test) Cough severity VAS Median 31.0 (9, 94) 23.0 (3, 88) 19.0 (0, 62) −11.0 (−93, 20) 0.003 Mean 39.8 (26.8) 33.6 (25.2) 19.8 (17.7) −19.3 (27.0) Cough urge VAS Median 26.0 (8, 94) 26.0 (2, 83) 19.0 (0, 61) −7.0 (−83, 42) 0.163 Mean 37.7 (24.9) 32.8 (23.1) 22.2 (18.4) −14.5 (28.3) LCQ Median 15.96 (5.07, 19.74) 17.6 (6.11, 20.75) 19.02 (14.93, 20.38) 1.85 (−1.17, 12.18) 0.006 Mean 14.63 (4.07) 16.68 (3.41) 18.23 (1.76) 3.47 (4.0) KSQ_GH Median 50.7 (23.8, 100) 61.9 (29.4, 100) 72.25 (39.9, 100) 16.3 (−13.8, 47.1) 0.001 Mean 53.2 (18.3) 63.0 (18.1) 69.63 (15.4) 17.2 (15.7) KSQ_lung Median 50.2 (29.0, 68.0) 52.6 (33.6, 77.1) 61.95 (41.6, 100) 6.5 (−1.3, 34.8) 0.001 Mean 52.0 (10.4) 54.5 (12.0) 62.5 (14.0) 10.7 (11.3) KSQ_lung_GH Median 58.1 (36.7, 74.7) 58.7 (41.9, 86.1) 66.25 (50.1, 91.5) 10.7 (−2.3, 26.8) 0.001 Mean 57.3 (9.1) 61.9 (11.6) 67.58 (10.4) 10.6 (8.3) Data are presented as median (range) and mean (sd). VAS: visual analogue scale; LCQ: Leicester cough questionnaire; KSQ: King's sarcoidosis questionnaire (presented as general health (GH), lung and combined lung-GH domains).
Vol 10 Issue 4
Table of Contents
“Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial”. Simon D. Fraser, Susannah Thackray-Nocera, Marica Shepherd, Rachel Flockton, Caroline Wright, Wayne Sheedy, Kayleigh Brindle, Alyn H. Morice, Paul M. Kaye, Michael G. Crooks and Simon P. Hart. ERJ Open Res 2020; 6: 00534-2020.
